Dissecting Interleukin-6 Classic and Trans-signaling in Inflammation and Cancer

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2023 Jun 24

PMID 37355548

Authors

Christoph Garbers

Stefan Rose-John

Affiliations

Soon will be listed here.

Abstract

Interleukin-6 (IL-6) is a cytokine synthesized by many cells in the human body. IL-6 binds to a membrane-bound receptor (IL-6R), which is only present on hepatocytes, some epithelial cells, and some leukocytes. The complex of IL-6 and IL-6R binds to the ubiquitously expressed receptor subunit gp130, which forms a homodimer and thereby initiates intracellular signaling, e.g., the JAK/STAT and MAPK pathways. Proteases can cleave the membrane-bound IL-6R from the cell surface and generate a soluble IL-6R (sIL-6R), which retains its ability to bind IL-6. The IL-6/sIL-6R complex associates with gp130 and induces signaling even on cells which do not express the IL-6R. This paradigm has been called IL-6 trans-signaling, whereas signaling via the membrane-bound IL-6R is referred to as classic signaling. We have generated several molecular tools to differentiate between both pathways and to analyze the consequences of cellular IL-6 signaling in vivo. One of these tools is soluble gp130Fc, which selectively inhibits IL-6 trans-signaling. This protein under the WHO name Olamkicept has successfully undergone phase II clinical trials in patients with autoimmune diseases. Here, in this chapter, we describe several molecular tools to differentiate between IL-6 classic and trans-signaling and to analyze the consequences of cellular IL-6 signaling in vivo.

Citing Articles

Peimine ameliorates LPS-induced acute lung injury by regulating Nrf2 and NF-κB pathways.

Huang H, Wang G, Zeng D Am J Transl Res. 2024; 16(10):5385-5397.

PMID: 39544744 PMC: 11558434. DOI: 10.62347/ULSH9862.

Evaluation of selected circulating cytokines from the IL-6 family - interleukin 6, oncostatin M, and cardiotrophin-1 - in gastro-entero-pancreatic and bronchial neuroendocrine tumours.

Strzelczyk J, Janas K, Strzelczyk J, Chelmecka E, Kajdaniuk D, Kos-Kudla B Contemp Oncol (Pozn). 2024; 28(2):114-120.

PMID: 39421708 PMC: 11480914. DOI: 10.5114/wo.2024.142584.

References

Scheller J, Chalaris A, Garbers C, Rose-John S . ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 2011; 32(8):380-7. DOI: 10.1016/j.it.2011.05.005. View

Harker J, Lewis G, Mack L, Zuniga E . Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science. 2011; 334(6057):825-9. PMC: 3388900. DOI: 10.1126/science.1208421. View

Kraakman M, Kammoun H, Allen T, Deswaerte V, Henstridge D, Estevez E . Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab. 2015; 21(3):403-16. DOI: 10.1016/j.cmet.2015.02.006. View

Barkhausen T, Tschernig T, Rosenstiel P, van Griensven M, Vonberg R, Dorsch M . Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med. 2011; 39(6):1407-13. DOI: 10.1097/CCM.0b013e318211ff56. View

Greenhill C, Rose-John S, Lissilaa R, Ferlin W, Ernst M, Hertzog P . IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol. 2010; 186(2):1199-208. DOI: 10.4049/jimmunol.1002971. View

Grivennikov S, Karin E, Terzic J, Mucida D, Yu G, Vallabhapurapu S . IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009; 15(2):103-13. PMC: 2667107. DOI: 10.1016/j.ccr.2009.01.001. View

Schmidt S, Schumacher N, Schwarz J, Tangermann S, Kenner L, Schlederer M . ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling. J Exp Med. 2018; 215(4):1205-1225. PMC: 5881468. DOI: 10.1084/jem.20171696. View

Boyce E, Rogan E, Vyas D, Prasad N, Mai Y . Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis. Ann Pharmacother. 2018; 52(8):780-791. DOI: 10.1177/1060028018761599. View

Rose-John S, Winthrop K, Calabrese L . The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017; 13(7):399-409. DOI: 10.1038/nrrheum.2017.83. View

10.

Bazan J . Haemopoietic receptors and helical cytokines. Immunol Today. 1990; 11(10):350-4. DOI: 10.1016/0167-5699(90)90139-z. View

11.

Garbers C, Hermanns H, Schaper F, Muller-Newen G, Grotzinger J, Rose-John S . Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 2012; 23(3):85-97. DOI: 10.1016/j.cytogfr.2012.04.001. View

12.

Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T . Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989; 58(3):573-81. DOI: 10.1016/0092-8674(89)90438-8. View

13.

Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T . Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990; 63(6):1149-57. DOI: 10.1016/0092-8674(90)90411-7. View

14.

Garbers C, Aparicio-Siegmund S, Rose-John S . The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol. 2015; 34:75-82. DOI: 10.1016/j.coi.2015.02.008. View

15.

Schaper F, Rose-John S . Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 2015; 26(5):475-87. DOI: 10.1016/j.cytogfr.2015.07.004. View

16.

Mullberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G . The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993; 23(2):473-80. DOI: 10.1002/eji.1830230226. View

17.

Mullberg J, Schooltink H, Stoyan T, Heinrich P, Rose-John S . Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. Biochem Biophys Res Commun. 1992; 189(2):794-800. DOI: 10.1016/0006-291x(92)92272-y. View

18.

Rose-John S, Heinrich P . Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 1994; 300 ( Pt 2):281-90. PMC: 1138158. DOI: 10.1042/bj3000281. View

19.

Jones S, Scheller J, Rose-John S . Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011; 121(9):3375-83. PMC: 3163962. DOI: 10.1172/JCI57158. View

20.

Rose-John S . IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012; 8(9):1237-47. PMC: 3491447. DOI: 10.7150/ijbs.4989. View